{"id":4888,"date":"2020-04-03T06:32:15","date_gmt":"2020-04-03T06:32:15","guid":{"rendered":"http:\/\/www.globalrecordsindia.com\/?p=4888"},"modified":"2020-04-08T09:44:28","modified_gmt":"2020-04-08T09:44:28","slug":"03-a-20","status":"publish","type":"post","link":"https:\/\/www.globalrecordsindia.com\/?p=4888","title":{"rendered":"India&#8217;s first NCE (new chemical entity) discovery drug. June 2013 ."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">India&#8217;s first new chemical entity (NCE)&nbsp;<strong>Lipaglyn (Saroglitazar)<\/strong>&nbsp;is discovered and developed indigenously by an Indian Pharmaceutical Company &#8230;Zydus Cadilla.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Zydus Cadilla<\/strong>&nbsp;announced a breakthrough in its research effots with Lipaglyn, a drug targeted at bridging a hitherto unmet healtcare need for treating diabetic dyslipidemia or hypertriglyceridemia in Type II diabetes, not controlled by statins.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lipaglyn is the world&#8217;s first drug for treating diabetic dyslipdemia and combines lipid-and glucose-lowering effects in a single molecule.&nbsp;Lipaglyn has an active ingredient Saroglitazar&nbsp;and is the world&#8217;s first glitazar to be approved anywhere in the world.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Discovered by Zydus Research Centre, the dedicated NCE research arm of Zydus Cadilla &#8211; the Ahmedabad headquartered group.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The drug has been approved for launch in India by the Drug Controller General of India (DCGI)and is expected to be in the market by 2014.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>India&#8217;s first new chemical entity (NCE)&nbsp;Lipaglyn (Saroglitazar)&nbsp;is discovered and developed indigenously by an Indian Pharmaceutical Company &#8230;Zydus Cadilla. Zydus Cadilla&nbsp;announced a breakthrough in its research effots with Lipaglyn, a drug targeted at bridging a hitherto unmet healtcare need for treating diabetic dyslipidemia or hypertriglyceridemia in Type II diabetes, not controlled by statins. Lipaglyn is the &hellip; <a href=\"https:\/\/www.globalrecordsindia.com\/?p=4888\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">India&#8217;s first NCE (new chemical entity) discovery drug. June 2013 .<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-4888","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=\/wp\/v2\/posts\/4888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4888"}],"version-history":[{"count":4,"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=\/wp\/v2\/posts\/4888\/revisions"}],"predecessor-version":[{"id":4939,"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=\/wp\/v2\/posts\/4888\/revisions\/4939"}],"wp:attachment":[{"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalrecordsindia.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}